arsenicals

Summary

Summary: Inorganic or organic compounds that contain arsenic.

Top Publications

  1. ncbi Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML
    Xiao Wei Zhang
    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China
    Science 328:240-3. 2010
  2. pmc PML targeting eradicates quiescent leukaemia-initiating cells
    Keisuke Ito
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 453:1072-8. 2008
  3. ncbi Mechanisms of action of arsenic trioxide
    Wilson H Miller
    Lady Davis Institute for Medical Research and Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal H3T 1E2, Quebec, Canada
    Cancer Res 62:3893-903. 2002
  4. ncbi Acute promyelocytic leukemia: from highly fatal to highly curable
    Zhen Yi Wang
    Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Riu Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai, China
    Blood 111:2505-15. 2008
  5. ncbi Curing APL through PML/RARA degradation by As2O3
    Valérie Lallemand-Breitenbach
    University Paris Diderot, Sorbonne Paris Cité, Hopital St Louis 1, avenue Claude Vellefaux, 75475 Paris, Cedex 10, France
    Trends Mol Med 18:36-42. 2012
  6. ncbi In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
    G Q Chen
    Shanghai Institute of Hematology, Rui Jin Hospital, Department of Biophysics, Shanghai Second Medical University, P R China
    Blood 88:1052-61. 1996
  7. ncbi Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
    Ghada Kchour
    Immunology Research Centre, Bu Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
    Blood 113:6528-32. 2009
  8. ncbi Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh
    Anna Lena Lindberg
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Environ Res 106:110-20. 2008
  9. pmc Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid
    David S Paul
    Department of Nutrition, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7461, USA
    Environ Health Perspect 115:734-42. 2007
  10. ncbi Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1
    Wenbin Qian
    Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China
    Leuk Res 31:329-39. 2007

Research Grants

Detail Information

Publications317 found, 100 shown here

  1. ncbi Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML
    Xiao Wei Zhang
    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China
    Science 328:240-3. 2010
    ..The identification of PML as a direct target of As2O3 provides new insights into the drug's mechanism of action and its specificity for APL...
  2. pmc PML targeting eradicates quiescent leukaemia-initiating cells
    Keisuke Ito
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 453:1072-8. 2008
    ....
  3. ncbi Mechanisms of action of arsenic trioxide
    Wilson H Miller
    Lady Davis Institute for Medical Research and Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal H3T 1E2, Quebec, Canada
    Cancer Res 62:3893-903. 2002
    ..This information will be critical to realizing the potential for synergy between arsenic trioxide and other chemotherapeutic agents, thus providing enhanced benefit in cancer therapy...
  4. ncbi Acute promyelocytic leukemia: from highly fatal to highly curable
    Zhen Yi Wang
    Shanghai Institute of Hematology and State Key Laboratory of Medical Genomics, Riu Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai, China
    Blood 111:2505-15. 2008
    ..In this article, we review the history of introduction of ATRA and ATO into clinical use and the mechanistic studies in understanding this model of cancer targeted therapy...
  5. ncbi Curing APL through PML/RARA degradation by As2O3
    Valérie Lallemand-Breitenbach
    University Paris Diderot, Sorbonne Paris Cité, Hopital St Louis 1, avenue Claude Vellefaux, 75475 Paris, Cedex 10, France
    Trends Mol Med 18:36-42. 2012
    ..As discussed below, arsenic binding, oxidation, sumoylation on PML nuclear bodies, and RNF4-mediated ubiquitination all contribute to the As(2)O(3)-triggered catabolism of PML/RARA...
  6. ncbi In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
    G Q Chen
    Shanghai Institute of Hematology, Rui Jin Hospital, Department of Biophysics, Shanghai Second Medical University, P R China
    Blood 88:1052-61. 1996
    ..Moreover, this apoptosis induction occurs independently of the retinoid pathway and may be mediated, at least partly, through the modulation of bcl-2, as well as PML-RAR alpha and/ or PML proteins...
  7. ncbi Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
    Ghada Kchour
    Immunology Research Centre, Bu Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
    Blood 113:6528-32. 2009
    ..Long-term follow up will clarify whether this will translate to disease cure. Overall, these clinical results strengthen the concept of oncogene-targeted cancer therapy...
  8. ncbi Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh
    Anna Lena Lindberg
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Environ Res 106:110-20. 2008
    ..Overall, exposure level of arsenic, gender and age explained at most 30% of the variation in the present study, indicating that genetic polymorphisms are the most important factor influencing the metabolism of inorganic arsenic...
  9. pmc Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methylarsonous acid
    David S Paul
    Department of Nutrition, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7461, USA
    Environ Health Perspect 115:734-42. 2007
    ....
  10. ncbi Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1
    Wenbin Qian
    Institute of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China
    Leuk Res 31:329-39. 2007
    ....
  11. pmc Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
    E M Rego
    Department of Human Genetics, Molecular Biology Program, and Department of Medicine, Molecular Therapeutics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:10173-8. 2000
    ....
  12. ncbi Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia
    E Lengfelder
    III Medizinische Universitätsklinik Mannheim, University of Heidelberg, Mannheim, Germany
    Leukemia 26:433-42. 2012
    ....
  13. ncbi Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells
    Zi Miao Liu
    Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    Biochem J 438:349-58. 2011
    ..Blockage of the PI3K/Akt pathway or TGIF expression combined with ATO treatment may be a promising strategy for HCC therapy...
  14. pmc All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
    Zhi Xiang Shen
    Shanghai Institute of Hematology, State Key Lab of Medical Genomics, Rui Jin Hospital, Shanghai Second Medical University, 197 Rui Jin Road II, Shanghai 200025, China
    Proc Natl Acad Sci U S A 101:5328-35. 2004
    ..In conclusion, the ATRA/As(2)O(3) combination for remission/maintenance therapy of APL brings much better results than either of the two drugs used alone in terms of the quality of CR and the status of the disease-free survival...
  15. ncbi Arsenical-based cancer drugs
    Pierre J Dilda
    UNSW Cancer Research Centre, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney 2052, Australia
    Cancer Treat Rev 33:542-64. 2007
    ..Mechanisms of action and selectivity and acute and chronic toxicities are discussed along with the prospects of this class of molecule...
  16. pmc Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia
    Hiba El Hajj
    Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon
    J Exp Med 207:2785-92. 2010
    ..Our demonstration that this drug combination targeting Tax stability abrogates tumor cell immortality but not short-term growth may foretell a favorable long-term efficiency of this regimen in patients...
  17. pmc Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
    Jiong Hu
    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine and Institute of Health Science, Chinese Academy of Sciences, Shanghai 200025, China
    Proc Natl Acad Sci U S A 106:3342-7. 2009
    ..These results demonstrate the high efficacy and minimal toxicity of ATRA/ATO treatment for newly diagnosed APL in long-term follow-up, suggesting a potential frontline therapy for de novo APL...
  18. ncbi The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure
    Anna Lena Lindberg
    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    Toxicol Appl Pharmacol 230:9-16. 2008
    ..Thus, it can be speculated that this is due to a programming effect of arsenic in utero...
  19. ncbi Families of arsenic transporters
    B P Rosen
    Dept of Biochemistry and Molecular Biology, Wayne State University, School of Medicine, Detroit, MI 48201, USA
    Trends Microbiol 7:207-12. 1999
    ..Yeasts extrude arsenite using Acr3p, a plasma membrane carrier protein, or sequester it in vacuoles as the glutathione conjugate using Ycf1p, an ABC transporter...
  20. ncbi Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML
    Stefan R Weisshaar
    Center for Molecular Medicine Cologne CMMC, Institute for Genetics, Zulpicher Strasse 47, 50674 Koln, Germany
    FEBS Lett 582:3174-8. 2008
    ..Polysumoylation of PML in response to ATO thus leads to its recognition and ubiquitylation by RNF4...
  21. ncbi Induction of autophagic cell death in malignant glioma cells by arsenic trioxide
    Takao Kanzawa
    Department of Neurosurgery, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 63:2103-8. 2003
    ..These findings suggest that As(2)O(3) at a clinically safe concentration may be an effective chemotherapeutic agent for malignant gliomas...
  22. ncbi How acute promyelocytic leukaemia revived arsenic
    Jun Zhu
    CNRS UPR 9051, Laboratoire associé du comité de Paris de la ligue contre le cancer, affilié à l Université de Paris VII, Hopital St Louis, 1 avenue C Vellefaux, 75475 Paris Cedex 10, France
    Nat Rev Cancer 2:705-13. 2002
    ..of arsenic trioxide to treat acute promyelocytic leukaemia has radically changed this view, providing new insights into the pathogenesis of this malignancy and raising hopes that arsenicals might be useful in treating other cancers.
  23. ncbi Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies
    Wen Chien Chou
    Department of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
    Curr Opin Hematol 12:1-6. 2005
    ..This paper reviews recent findings that reveal why a traditional poison has become a magical potion for a major type of APL, which is characterized by a balanced chromosomal translocation t(15;17)...
  24. pmc Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
    James Kim
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
    Cancer Cell 23:23-34. 2013
    ..Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMO(D477G) medulloblastoma...
  25. ncbi Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
    Vikram Mathews
    Department of Haematology, Christian Medical College and Hospital, Vellore 632004, India
    Blood 107:2627-32. 2006
    ..Additionally, this regimen has minimal toxicity and can be administered on an outpatient basis after remission induction...
  26. ncbi Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
    Pawan Kumar
    Department of Biologic and Materials Sciences, University of Michigan School of Dentistry, 1011 North University Avenue, Room no 5205, Ann Arbor, MI 48109, USA
    Mol Cancer Ther 7:2060-9. 2008
    ..These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation...
  27. ncbi Arsenic trioxide uptake by human and rat aquaglyceroporins
    Zijuan Liu
    Department of Biochemistry and Molecular Biology, Wayne State University, School of Medicine, Detroit, MI 48201, USA
    Biochem Biophys Res Commun 316:1178-85. 2004
    ..The results support the hypothesis that arsenic trioxide and glycerol use the same translocation pathway in AQP9...
  28. ncbi The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects
    Ann M Bode
    The Hormel Institute, University of Minnesota, 801 16th Avenue NE, Austin, MN 55912, USA
    Crit Rev Oncol Hematol 42:5-24. 2002
    ..The primary purpose of this review is to examine recent findings, from this laboratory and others, that focus on the molecular mechanisms of arsenic's actions in cell transformation and as a therapeutic agent...
  29. ncbi JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells
    Kelly Davison
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Blood 103:3496-502. 2004
    ....
  30. pmc Genetic association between intronic variants in AS3MT and arsenic methylation efficiency is focused on a large linkage disequilibrium cluster in chromosome 10
    Paulina Gomez-Rubio
    Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona 85721 0207, USA
    J Appl Toxicol 30:260-70. 2010
    ..The results reported here should be carefully considered for future genomic association studies involving AS3MT and arsenic metabolism...
  31. ncbi Noninvasive imaging of cell death using an Hsp90 ligand
    Danielle Park
    Lowy Cancer Research Centre and POW Clinical School, University of New South Wales, Sydney, NSW 2052, Australia
    J Am Chem Soc 133:2832-5. 2011
    ..Tumor cell death in mice was noninvasively imaged by SPECT/CT using an (111)In-tagged compound. This versatile compound should enable the imaging of cell death in most experimental settings...
  32. ncbi Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin
    Hui Wen Chiu
    Department of Environmental and Occupational Health, National Cheng Kung University Medical College, 138 Sheng Li Road, Tainan 704, Taiwan
    J Mol Med (Berl) 89:927-41. 2011
    ..This study suggests that ATO treatment or survivin inhibition could be a novel therapeutic strategy in malignant gliomas...
  33. pmc Arsenic detoxification and evolution of trimethylarsine gas by a microbial arsenite S-adenosylmethionine methyltransferase
    Jie Qin
    Department of Biochemistry and Molecular Biology, Wayne State University, Detroit, MI 48201, USA
    Proc Natl Acad Sci U S A 103:2075-80. 2006
    ..The net result is loss of arsenic, from both the medium and the cells. Because ArsM homologues are widespread in nature, this microbial-mediated transformation is proposed to have an important impact on the global arsenic cycle...
  34. ncbi How I treat adult T-cell leukemia/lymphoma
    Ali Bazarbachi
    Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    Blood 118:1736-45. 2011
    ..To prevent relapse, clinical trials assessing consolidative targeted therapies such as arsenic/IFN combination or novel monoclonal antibodies are needed. Finally, allogeneic BM transplantation should be considered in suitable patients...
  35. ncbi Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells
    Abdullah Baysan
    Cellular and Molecular Immunology Laboratory, Division of Basic and Clinical Immunology, University of California, Irvine, CA 92697, USA
    Int J Oncol 30:313-8. 2007
    ..Altogether, these data indicate that As2O3 induces apoptosis in B cells, regardless of Bcl-2 expression, via the mitochondrial pathway by enhancing oxidative stress...
  36. pmc Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions
    Kathleen M McCarty
    Yale University School of Medicine, Epidemiology and Public Health, Division of Environmental Health Sciences, New Haven, Connecticut 06520, USA
    Environ Health Perspect 115:341-5. 2007
    ..We investigated whether primary and secondary arsenic methylation ratios were associated with skin lesions and whether GSTT1, GSTP1, and GSTM1 polymorphisms modify these relationships...
  37. ncbi All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
    Harry J Iland
    Royal Prince Alfred Hospital, Camperdown, Australia
    Blood 120:1570-80; quiz 1752. 2012
    ..This trial was registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) as ACTRN12605000070639...
  38. ncbi The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells
    Xi Chen
    General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, P R China
    Oncol Rep 22:73-80. 2009
    ..These two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, may be useful for studying the mechanism of arsenic resistance in solid tumors and may provide a way to overcome it...
  39. ncbi Anion exchanger 2 mediates the action of arsenic trioxide
    Xiao Yan Pan
    Department of Pathophysiology, Shanghai Jiao Tong University, School of Medicine
    Br J Haematol 134:491-9. 2006
    ..In conclusion, AE2 mediated the action of arsenic trioxide via regulation of intracellular pH and a novel pathway for the mechanism of action of arsenic trioxide is reported...
  40. ncbi Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors
    Caroline Diepart
    Biomedical Magnetic Resonance Group, Louvain Research Institute, Universite Catholique de Louvain, Brussels, Belgium
    Cancer Res 72:482-90. 2012
    ..Together, our findings show that As(2)O(3) acutely increases oxygen consumption and radiosensitizes tumors, providing a new rationale for clinical investigations of As(2)O(3) in irradiation protocols to treat solid tumors...
  41. ncbi Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide
    L Vernhet
    INSERM U456, Detoxication et Reparation Tissulaire, Faculte des Sciences Pharmaceutiques et Biologiques, 2 avenue Léon Benard, F 35043 céedex, Rennes, France
    Biochem Pharmacol 61:1387-91. 2001
    ..These results indicate that MRP1 overexpression in human tumor cells can confer resistance to As2O3, which may limit the clinical use of this anticancer drug for treatment of MRP1-positive tumors...
  42. pmc Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis
    Alejo A Morales
    Department of Microbiology and Immunology and the Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
    J Biol Chem 284:12886-95. 2009
    b>Arsenicals are both environmental carcinogens as well as therapeutic agents for the treatment of trypanosomiasis and more recently cancer...
  43. ncbi Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage
    Y Shen
    Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Second Medical University, PR China
    Leukemia 15:735-41. 2001
    ..2865 and 0.7146, respectively). In conclusion, we demonstrated that low-dose As2O3 had the same effect as the conventional dosage and the mechanism of low-dose arsenic seemed to primarily induce differentiation of APL cells...
  44. pmc A pathway-based analysis of urinary arsenic metabolites and skin lesions
    Molly L Kile
    Department of Environmental Health, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Am J Epidemiol 173:778-86. 2011
    ..This novel analysis confirmed that persons who excrete a higher proportion of MMA have a greater risk of skin lesions after data are adequately controlled for urinary arsenic metabolites, current arsenic exposure, and other risk factors...
  45. ncbi Arsenic metabolites in human urine after ingestion of an arsenosugar
    Kevin A Francesconi
    Institute of Biology, University of Southern Denmark, 5230 Odense M, Denmark
    Clin Chem 48:92-101. 2002
    ..Arsenic-containing carbohydrates (arsenosugars) are common constituents of marine algae, including those species used as human food. The toxicology of these compounds has not been fully evaluated...
  46. ncbi Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid
    Jing Jing Li
    Department of Pharmacology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    Acta Pharmacol Sin 27:1078-84. 2006
    ..The present study was designed to determine the possible pathway underlying the enhancement of apoptosis induced by the combined use of arsenic trioxide (As(2)O(3)) and ascorbic acid (AA)...
  47. ncbi Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours
    R J Griffin
    Department of Therapeutic Radiology Radiation Oncology, University of Minnesota Medical School, 420 Delaware St S E, MMC 494, Minneapolis, MN 55455, USA
    Int J Hyperthermia 19:575-89. 2003
    ....
  48. ncbi Evidence against the nuclear in situ binding of arsenicals--oxidative stress theory of arsenic carcinogenesis
    Kirk T Kitchin
    Environmental Carcinogenesis Division, Mail Drop B143 06, National Health and Environmental Effects Research Laboratory, U S Environmental Protection Agency, Research Triangle Park, NC 27711, USA
    Toxicol Appl Pharmacol 232:252-7. 2008
    A large amount of evidence suggests that arsenicals act via oxidative stress in causing cancer in humans and experimental animals...
  49. ncbi Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan
    Yung Kai Huang
    Graduate Institute of Medical Sciences, School of Medicine, Taipei Medical University, Taipei, Taiwan
    Toxicol Appl Pharmacol 218:135-42. 2007
    ..This study further explored the association between arsenic methylation capability and hypertension risk among residents of arseniasis-hyperendemic areas in Taiwan considering the effect of CAE and other potential confounders...
  50. ncbi Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico
    Maria Mercedes Meza
    Department of Natural Resources, ITSON, Cd Obregón, Sonora 85000, Mexico
    Environ Res 96:119-26. 2004
    ..The difference in the proportion of urinary arsenic metabolites in those towns may be due to genetic polymorphisms in the As methylating enzymes of these populations...
  51. pmc What do we feed to food-production animals? A review of animal feed ingredients and their potential impacts on human health
    Amy R Sapkota
    Johns Hopkins Center for a Livable Future, Bloomberg School of Public Health, Baltimore, Maryland, USA
    Environ Health Perspect 115:663-70. 2007
    ..In this article we review current U.S. animal feeding practices and etiologic agents that have been detected in animal feed. Evidence that current feeding practices may lead to adverse human health impacts is also evaluated...
  52. ncbi Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA
    Tanja Schwerdtle
    Institut für Lebensmittelchemie und Toxikologie, Universitat Karlsruhe, Germany
    Carcinogenesis 24:967-74. 2003
    ..Thus, biomethylation of inorganic arsenic may be involved in inorganic arsenic-induced genotoxicity/carcinogenicity...
  53. ncbi Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine
    H Maeda
    Laboratory of Functional Biology, Kyoto University Graduate School of Biostudies, Kyoto 606 8501, Japan
    Cell Death Differ 11:737-46. 2004
    ..Furthermore, because the effective doses of both compounds are within clinically achievable range, this report will lead to immediate benefit for the development of a new cancer therapy...
  54. ncbi Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
    Y Jing
    Rochelle Belfer Chemotherapy Foundation Laboratory, Division of Neoplastic Diseases, Department of Medicine, Mount Sinai Medical Center, New York, NY, USA
    Blood 94:2102-11. 1999
    ....
  55. ncbi Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis
    Fumihiko Hayakawa
    Section of Microbiology, Division of Biological Sciences, University of California at Davis, Davis, CA 95616, USA
    Cancer Cell 5:389-401. 2004
    ..We conclude that phosphorylation by MAP kinase cascades potentiates the antiproliferative functions of PML and helps mediate the proapoptotic effects of As(2)O(3)...
  56. ncbi Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies
    Dan Douer
    University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Rm 3460, Los Angeles, CA 90033, USA
    J Clin Oncol 23:2396-410. 2005
    ..This article reviews the clinical use of arsenic trioxide to date and discusses new therapeutic strategies evolving from its diverse biologic activities...
  57. ncbi Mechanisms of arsenic biotransformation
    Marie Vahter
    Institute of Environmental Medicine, Karolinska Institutet, Box 210, 171 777 Stockholm, Sweden
    Toxicology 181:211-7. 2002
    ..There are indications that subjects with low MMA in urine have faster elimination of ingested arsenic, compared to those with more MMA in urine...
  58. pmc Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals
    David J Thomas
    Pharmacokinetics Branch, Experimental Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC 27711, USA
    Exp Biol Med (Maywood) 232:3-13. 2007
    ..of inorganic arsenic into methylated products is a multistep process that yields mono-, di-, and trimethylated arsenicals. In recent years, it has become apparent that formation of methylated metabolites of inorganic arsenic is not ..
  59. ncbi Genetic and epigenetic effects of environmental arsenicals
    Toby G Rossman
    The Nelson Institute of Environmental Medicine, NYU Langone School of Medicine, 57 Old Forge Road, Tuxedo, NY 10987, USA
    Metallomics 3:1135-41. 2011
    ..Effects of trivalent arsenicals on poly(ADP ribose) polymerase and P53 activation may mediate effects on DNA repair and aneuploidy...
  60. ncbi How I treat acute promyelocytic leukemia
    Martin S Tallman
    Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Blood 114:5126-35. 2009
    ..Acute promyelocytic leukemia should be considered in any patient with newly diagnosed acute myeloid leukemia because the treatment is urgent and different from all other subtypes...
  61. ncbi Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL
    Qun Liu
    University of Texas Health Science Center, San Antonio, TX, USA
    Blood 101:4078-87. 2003
    ..Our results justify the use of the combination of these 2 drugs in clinical setting in myeloma patients...
  62. ncbi Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
    Y S Lew
    Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Cancer Res 59:6033-7. 1999
    ..Normal skin, muscle, and kidney were relatively unaffected by arsenic trioxide. These results suggest that the drug may be investigated as an adjunct to the standard cancer therapeutic modalities...
  63. ncbi Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes
    Felecia S Walton
    Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7224, USA
    Toxicol Appl Pharmacol 198:424-33. 2004
    ..We have examined effects of iAs and methylated arsenicals that contain trivalent or pentavalent arsenic on glucose uptake by 3T3-L1 adipocytes...
  64. pmc A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer
    Richard W Ahn
    Department of Chemistry, Chemistry of Life Processes Institute, Evanston, Illinois 60208, USA
    Clin Cancer Res 16:3607-17. 2010
    ..We postulated that nanobin encapsulation of As(2)O(3) would improve its therapeutic index against clinically aggressive solid tumors, such as triple-negative breast carcinomas...
  65. ncbi Introduction: the history of arsenic trioxide in cancer therapy
    K H Antman
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Oncologist 6:1-2. 2001
    ..Randomized clinical trials in the U.S. led to FDA approval of arsenic trioxide for relapsed or refractory APL in September 2000...
  66. ncbi Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis
    Hui Wen Chiu
    Department of Environmental and Occupational Health, National Cheng Kung University, Medical College, Tainan, Taiwan
    Autophagy 6:353-65. 2010
    ..The data suggest that a combination of IR and ATO could be a new potential therapeutic strategy for the treatment of fibrosarcoma...
  67. pmc Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
    ..The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed...
  68. ncbi Modern approaches to treating acute promyelocytic leukemia
    Miguel A Sanz
    Hematology Department, University Hospital La Fe, Avda Companar 21, Valencia, 46009 Spain
    J Clin Oncol 29:495-503. 2011
    ..In this review article, we discuss most recent advances in the treatment of patients with newly diagnosed and relapsed APL...
  69. ncbi Arsenicals affect base excision repair by several mechanisms
    Franziska Ebert
    Institute of Food Chemistry, University of Munster, Corrensstrasse 45, 48149 Munster, Germany
    Mutat Res 715:32-41. 2011
    ....
  70. ncbi Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation
    Javier Redondo-Muñoz
    Departamento de Medicina Celular y Molecular, Hospital Universitario Puerta de Hierro, Madrid, Spain
    Clin Cancer Res 16:4382-91. 2010
    ..We sought to study the mechanism involved in this effect and whether ATO is suitable for combination therapies with protein kinase inhibitors...
  71. pmc Variability in biomarkers of arsenic exposure and metabolism in adults over time
    Molly L Kile
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Environ Health Perspect 117:455-60. 2009
    ..Urinary arsenic metabolites (UAs) are used as biomarkers of exposure and metabolism...
  72. pmc Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide
    Jun Lu
    Medical Nobel Institute for Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, SE 17177 Stockholm, Sweden
    Proc Natl Acad Sci U S A 104:12288-93. 2007
    ..Blocking cancer cell DNA replication and repair and induction of oxidative stress by the inhibition of both Trx and GSH systems are suggested as cancer chemotherapeutic strategies...
  73. ncbi Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
    Ardeshir Ghavamzadeh
    Hematology, Oncology, and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Kargar Ave, Tehran, Iran
    J Clin Oncol 29:2753-7. 2011
    ..Several studies have shown high efficacy of single-agent arsenic trioxide in newly diagnosed APL. However, long-term follow-up results are needed...
  74. ncbi History of the development of arsenic derivatives in cancer therapy
    S Waxman
    Rochelle Belfer Chemotherapy Foundation Laboratory, Mt Sinai School of Medicine, New York, New York 10029, USA
    Oncologist 6:3-10. 2001
    ..Molecular studies and ongoing clinical trials suggest that, as a chemotherapeutic agent, arsenic trioxide shows great promise in the treatment of malignant disease...
  75. ncbi Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3
    Takao Kanzawa
    Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 24:980-91. 2005
    ..This study adds a new concept to characterize the pathways by which As(2)O(3) acts to induce autophagic cell death in malignant glioma cells...
  76. ncbi Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water
    E M Kenyon
    Experimental Toxicology Division, Mail Stop B143 01, National Health and Environmental Effects Research Laboratory, Office of Research and Development, U S Environmental Protection Agency, Research Triangle Park, NC 27711, USA
    Toxicol Appl Pharmacol 232:448-55. 2008
    ..pharmacokinetic models for arsenic metabolism and disposition need to include mechanisms for organ-specific accumulation of some arsenicals and that urinary metabolite profiles are not necessarily reflective of target tissue dosimetry.
  77. pmc Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells
    Pei Chih Lee
    Institute of Pharmacology, School of Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
    Neoplasia 12:376-87. 2010
    ..Taken together, the present study reveals that a combination of bifunctional alkylating agents and ATO may be a rational strategy for treating cancers with inherited or acquired drug resistance...
  78. ncbi Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism
    Tain Junn Cheng
    Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, 138 Sheng Li Road, Tainan 704, Taiwan
    Toxicol Appl Pharmacol 256:146-53. 2011
    ..For decreasing atherosclerosis related mortality associated with arsenic, preventing exposure from environmental sources in early life is an important element...
  79. pmc Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets
    Christelle Douillet
    Department of Nutrition, Gillings School of Global Public Health, 2302 MHRC, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7461, USA
    Toxicol Appl Pharmacol 267:11-5. 2013
    ..Our present study examined effects of the trivalent arsenicals on insulin secretion by intact pancreatic islets isolated from C57BL/6 mice...
  80. ncbi Cytotoxicity of arsenic trioxide to transitional carcinoma cells
    Yeong Shiau Pu
    Department of Urology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, Republic of China
    Urology 60:346-50. 2002
    ....
  81. ncbi Determination of arsenic speciation in poultry wastes by IC-ICP-MS
    B P Jackson
    Advanced Analytical Center for Environmental Sciences, Savannah River Ecology Laboratory, University of Georgia, Aiken, South Carolina 29802, USA
    Environ Sci Technol 35:4868-73. 2001
    ..This methodology should prove useful in identifying organoarsenic compounds and the more toxic inorganic species in soils subject to poultry litter application...
  82. ncbi Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents
    Feirong Gong
    Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, China
    Acta Biomater 6:534-46. 2010
    ..8%, 32.5% and 31.2%, respectively. The As(2)O(3)-eluting stent using Hep-Co90 as the drug carrier and stent coating material presented in this study represents a novel promising device in preventing in-stent restenosis...
  83. ncbi The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells
    Young Hee Kang
    Laboratory of Molecular Biochemistry, Department of Chemistry, Hanyang University, Seoul, South Korea
    J Cell Physiol 217:23-33. 2008
    ....
  84. pmc As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity
    Lionel Berthoux
    Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Virol 77:3167-80. 2003
    ..In summary, As(2)O(3) stimulates retroviral reverse transcription, perhaps via effects on mitochondria, and provides a useful tool for characterizing Ref1...
  85. pmc Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic
    Olga L Valenzuela
    Sección de Toxicología, CINVESTAV IPN, Mexico DF, Mexico
    Environ Health Perspect 113:250-4. 2005
    ..Notably, methylated trivalent arsenicals were detected in 98% of analyzed urine samples...
  86. ncbi Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide
    W Y Au
    University Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
    Br J Haematol 117:130-2. 2002
    ..Our results suggest a synergistic therapeutic effect between As2O3 and ATRA in APL in advanced relapse...
  87. ncbi A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation
    Hyeon Ok Jin
    Laboratory of Radiation Resistance Control, Korea Institute of Radiological and Medical Sciences, Nowon Gu, Seoul, Republic of Korea
    Lung Cancer 61:317-27. 2008
    ..In conclusion, in H1299 human NSCLC cells, sulindac and ATO synergistically induce a high degree of apoptosis, which is mediated by the ROS-dependent JNK activation pathway via Bcl-xL phosphorylation...
  88. ncbi Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression
    Azra Raza
    Section of Myeloid Diseases and MDS Center, Rush University, Rush Presbyterian St Luke s Medical Center, 2242 West Harrison Street, Suite 108, Chicago, IL 60612 3515, USA
    Leuk Res 28:791-803. 2004
    ..Both low/high risk MDS may benefit significantly from therapy with ATO/thalidomide, and those with high pre-therapy EVI1 expression may be uniquely sensitive...
  89. ncbi Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria
    Young Hee Kang
    Laboratory of Radiation Effect and Laboratory of Cell Biology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
    Cancer Res 64:8960-7. 2004
    ..These data support a notion that ROS-mediated PARP-1 activation signals AIF release from mitochondria, resulting in activation of a caspase-independent pathway of cell death in solid tumor cells by As(2)O(3) treatment...
  90. pmc BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells
    Zhu Yuan
    State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
    PLoS ONE 6:e20586. 2011
    ..Previous reports indicated that arsenic trioxide (ATO) induces cell apoptosis in both drug-sensitive and -resistant ovarian cancer cells...
  91. ncbi As2O3-induced oxidative stress and cycle progression in a human intestinal epithelial cell line (Caco-2)
    J M Laparra
    Instituto de Agroquimica y Tecnologia de Alimentos CSIC, Apdo 73, 46100 Burjassot, Valencia, Spain
    Toxicol In Vitro 22:444-9. 2008
    ..Oxidative stress and alteration of mitochondrial functionality could be early indicators of arsenic-induced cytotoxicity, with the resulting abnormal progression of the cell cycle...
  92. ncbi Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells
    Woong Shick Ahn
    Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, 505 Banpo Dong, Seocho Ku, Seoul 137 040, Korea
    Oncol Rep 12:573-80. 2004
    ....
  93. ncbi Arsenic trioxide and acute promyelocytic leukemia: clinical and biological
    Z Chen
    Shanghai Institute of Hematology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, 197 Rui Jin Road II, 200025 Shanghai, People s Republic of China
    Curr Top Microbiol Immunol 313:129-44. 2007
    ..Indeed, arsenic trioxide combined with all-trans retinoic acid shows a synergistic effect. Mechanistically, arsenic targets the key leukemogenic protein PML-RARalpha, setting up a new example of molecular target-based cancer therapy...
  94. ncbi Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in drinking water
    W Jay Christian
    Markey Cancer Control Program, University of Kentucky, Lexington, KY, USA
    Environ Res 100:115-22. 2006
    ..The results of this study suggest that in populations exposed to arsenic, Se intake may be correlated with urinary As excretion, and may alter As methylation...
  95. ncbi Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects
    Germano Baj
    Laboratories of Gynecologic Oncology, University of Eastern Piedmont A Avogadro, Novara, Italy
    Breast Cancer Res Treat 73:61-73. 2002
    ....
  96. ncbi Molecular targets of arsenic trioxide in malignant cells
    Wilson H Miller
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital and McGill University Department of Oncology, Montreal, Quebec, Canada
    Oncologist 7:14-9. 2002
    ..A better understanding of the mechanisms of action of ATO may help guide the use of ATO for the treatment of a wide variety of malignancies and allow its potential in cancer therapy to be fully realized...
  97. ncbi Study on the toxic effects induced by different arsenicals in primary cultured rat astroglia
    Yaping Jin
    Department of Occupational and Environmental Health, School of Public Health, China Medical University, Shenyang, Liaoning, PR China
    Toxicol Appl Pharmacol 196:396-403. 2004
    ..study were to determine if the toxic effects on primary cultured rat astroglia would be induced by different arsenicals. Based on alamarBlue assay and the single cell gel electrophoresis (SCGE, comet assay), the cell viability and ..
  98. ncbi Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state
    Ronald B Gartenhaus
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Chicago, IL 60611, USA
    Clin Cancer Res 8:566-72. 2002
    ....
  99. ncbi Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo
    Xinyan Zhang
    Beijing Institute of Dental Research, Beijing Stomatological Hospital and School of Stomatology, Capital Medical University, No 4 Tiantanxili, Dongcheng District, Beijing, China
    Cancer Lett 318:93-8. 2012
    ..Our study clearly demonstrated opposite effects of ATO on Nrf2 pathway in OSCC cells in vitro and in vivo...
  100. ncbi Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells
    Guo Qiang Chen
    Department of Pathophysiology, Shanghai Second Medical University, Shanghai, China
    Cancer Res 63:1853-9. 2003
    ..MAs(III)O as an apoptotic inducer should be considered in the treatment of other hematologic malignancies like lymphoma...
  101. pmc Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells
    Clement Yedjou
    Cellomics and Toxicogenomics Research Laboratory, NIH RCMI Center for Environmental Health, College of Science, Engineering and Technology, Jackson State University, 1400 Lynch Street, Box 18540, Jackson, Mississippi, USA
    J Hematol Oncol 3:28. 2010
    ..In a recently published study we demonstrated that ATO pharmacology as an anti-cancer drug is associated with its cytotoxic and genotoxic effects in human leukemia cells...

Research Grants65

  1. DENDRITIC CELL THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA
    Mark Litzow; Fiscal Year: 2003
    ..The combined data will provide a comprehensive understanding of the interaction of the immune system and CML and will yield information required for the rational design of more effective clinical protocols in the future. ..
  2. CLINICAL RESEARCH METHODOLOGY CURRICULUM
    Dean Bajorin; Fiscal Year: 2004
    ..abstract_text> ..
  3. Epigenetic Remodeling by Environmental Arsenicals
    Bernard Futscher; Fiscal Year: 2009
    ..proposed study is designed to identify mechanisms of toxicity that are a result of environmental exposures to arsenicals. It is hypothesized that arsenical toxicity, in part, is mediated through its disruption of the normal ..
  4. Developing a murine model for arsenic-induced skin neoplasm
    Mohammad Athar; Fiscal Year: 2010
    ..However, the mechanism(s) underlying the carcinogenicity of arsenicals remains elusive particularly due to unavailability of suitable murine model...
  5. Environmental arsenic and diabetes mellitus
    Miroslav Styblo; Fiscal Year: 2012
    ..of these mice, including liver, pancreas, adipose and skeletal muscle tissues, was represented by methylated arsenicals, the products of the methylation of iAs by arsenic (3+ oxidation state) methyltransferase (AS3MT)...
  6. Arsenic-induced apoptosis in myeloma
    Lawrence H Boise; Fiscal Year: 2013
    b>Arsenicals have been used in medicine for centuries however their re-emergence in the treatment of cancer has only occurred in the last 15 years...
  7. Pesticide Exposures and Risk of Preterm Birth
    Gary M Shaw; Fiscal Year: 2013
    ..g., carbamates, halogenated hydrocarbons, and arsenicals) of pesticides during pregnancy are associated with >100,000 women spontaneously delivering infants/fetuses ..
  8. Human N6AMT1 and Its Regulation of Arsenic Biomethylation and Toxicity
    Xuefeng Ren; Fiscal Year: 2013
    ..is primarily metabolized by AS3MT to yield both trivalent and pentavalent mono- and less toxic dimethylated arsenicals. Variability in arsenic biomethylation and the resulting changes of arsenic metabolite profiles contribute to ..
  9. Impact of Arsenicals on Selenoprotein Synthesis
    William Self; Fiscal Year: 2006
    ..Based on these observations, our hypothesis is that the increase in ROS observed in cells treated with arsenicals is due to inhibition of SPS and subsequent decreased levels of thioredoxin reductase (TrxR) and glutathione ..
  10. Optimized Hydride Generation Systems for Arsenic Specia*
    Miroslav Styblo; Fiscal Year: 2006
    ..iAs) in humans involves reduction and methylation reactions that produce methylated trivalent and pentavalent arsenicals. The liver is likely the major site for methylation of iAs in human body...
  11. BIOCHEMICAL STUDIES OF ARSENITE AND SULFITE OXIDASE
    Russ Hille; Fiscal Year: 1990
    ..electron transport system will be investigated and its significance in the metabolism of environmental arsenicals assessed. Sulfite oxidase is a molybdoheme enzyme isolated from liver of a variety of vertebrates...
  12. LUNG METABOLISM & TOXICITY OF ENVIRONMENTAL ARSENICALS
    DEAN CARTER; Fiscal Year: 1993
    ..This includes an investigation of how the lung cells protect themselves from the toxic effects of arsenicals, particularly in their ability to bind and/or metabolize arsenical compounds to modulate cellular toxicity...
  13. Chemical Genetic Approach to Melanocyte Chemosensitivity
    Seth Orlow; Fiscal Year: 2004
    ..p) gene product has been implicated in controlling melanocyte sensitivity to cytotoxic compounds including arsenicals and cisplatin...
  14. PHASE II STUDY OF ARSENIC TRIOXIDE IN LEUKEMIA
    Janice Dutcher; Fiscal Year: 2000
    ..However, neurologic toxicity is well documented in non-therapeutic reports and is a major concern in the use of arsenicals. This study includes intensive pre-, intra-, and post-administration neurologic evaluations for evidence of ..
  15. Proteomic determination of arsenical action
    Partha Basu; Fiscal Year: 2005
    ..2) To use a novel proteomic approach to investigate the transient effects of arsenic and arsenicals on cell signaling proteins...
  16. PP2A-Like Constitutive ERK/MAPK Phosphatase in Brain
    Timothy Foley; Fiscal Year: 2003
    ....
  17. Arsenic Trioxide Down-Regulates STAT3 Activity in AML
    Meir Wetzler; Fiscal Year: 2004
    ..In addition, we will attempt to identify the mode by which ATO controls the activity of STAT3 and how this effect alters the gene profile patterns and induces apoptosis. ..
  18. Metabolism and Toxicity of Arsenic in the Human Liver
    Miroslav Styblo; Fiscal Year: 2010
    ..laboratory, clinical and population studies suggest that the AS3MT-catalyzed formation of methylated trivalent arsenicals, MAsIII or DMAsIII, is an important mechanism for activation of iAs as a toxin and carcinogen and that these ..
  19. Mechanism of Arsenic-Induced Diabetes
    Miroslav Styblo; Fiscal Year: 2002
    DESCRIPTION (provided by applicant) This project examines the role of arsenicals in the induction of diabetes mellitus. Inorganic forms of arsenic (iAs) are highly toxic and are classified as human carcinogens...
  20. ARSENIC, OXIDATIVE STRESS, AND TRANSCRIPTIONAL CONTROL
    Miroslav Styblo; Fiscal Year: 2002
    ..Effects of iAs and trivalent and pentavalent methylated arsenicals on cell viability and proliferation, cellular redox status, induction of oxidative stress, and expression or ..
  21. Nutritional Influences on Aresenic Toxicity
    Mary Gamble; Fiscal Year: 2006
    ..abstract_text> ..
  22. Antioxidant Functions of Lipoic Acid
    James May; Fiscal Year: 2004
    ..Despite the widespread use of lipoic acid, these studies are necessary to establish the biological basis and rationale for the clinical use of the agent. ..
  23. Therapeutic effect of boswellin in prostate cancer
    Yongkui Jing; Fiscal Year: 2005
    ..We hope our proposal will lead to the discovery of a novel complementary agent for prostate cancer treatment. ..
  24. Bacterial Cell Surfaces Gordon Conference
    Barry Rosen; Fiscal Year: 2004
    ..abstract_text> ..
  25. Technology for DNA Damage Analysis and Biomarkers
    X Le; Fiscal Year: 2004
    ..The technology will also be useful for monitoring DNA damage induced by anticancer agents and for studying DNA repair, which is an essential protection mechanism against cancer initiation. ..
  26. Antioxidant vitamins in models of Alzheimer's Disease
    James May; Fiscal Year: 2008
    ..If antioxidant vitamins ameliorate toxicity in cell and animal models of Alzheimer's disease, then oxidant stress is involved in disease progression, and antioxidant vitamin supplements may be beneficial. ..
  27. Antioxidant Interaction of Selenium and Vitamins C & E
    James May; Fiscal Year: 2008
    ..Using this approach, it will be possible to relate the crucial, mitochondrial functions of selenium and vitamins C and E to the antioxidant defenses of the whole animal. ..
  28. Mechanism of combined 'epigenetic therapy' in myeloid malignancies
    Steven Gore; Fiscal Year: 2009
    ....
  29. MOLECULAR BASIS OF ORGANELLE MOVEMENT IN AXONS
    Michael Sheetz; Fiscal Year: 2002
    ....
  30. Hyaluronan and erbBs regulate cardiac valve formation
    Todd Camenisch; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  31. Factor B and energy coupling in mitochondria
    GRIGORY BELOGRUDOV; Fiscal Year: 2007
    ..The proposed research is expected to advance the knowledge of the molecular mechanisms of energy transfer and conservation in mitochondria, and shed light on the role of mitochondria in a number of human disorders. ..
  32. Biophysical Properties of Membranes: Lipid-Protein Bonds
    Michael Sheetz; Fiscal Year: 2006
    ..abstract_text> ..
  33. STRUCTURE AND ASSEMBLY OF CYTOSKELETAL FILAMENTS
    Michael Sheetz; Fiscal Year: 2009
    ....
  34. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2008
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. [unreadable] [unreadable] [unreadable]..
  35. Redox Control of Radiation Response
    John Biaglow; Fiscal Year: 2006
    ..Ultimately, we hope to develop specific strategies for modifying thiol redox homeostasis in vivo, to make human tumors more sensitive to ionizing radiation. ..
  36. Sequestration and immobilization of metal and metalloid contaminants in sediments
    PEGGY O DAY; Fiscal Year: 2009
    ..abstract_text> ..
  37. Acupuncture for hot flashes in prostate cancer patients
    TOMASZ BEER; Fiscal Year: 2004
    ..The overall goal is to provide prostate cancer patients an effective, low toxicity, non-pharmacologic treatment modality for hot flashes. ..
  38. Use of GIS in analyzing environmental cancer risks as a*
    Robin Harris; Fiscal Year: 2003
    ..abstract_text> ..
  39. DYNAMICS OF SIGNAL TRANSDUCTION IN NEURONS
    Roger Tsien; Fiscal Year: 2006
    ..Such new techniques should help explore the biochemical mechanisms of long-term depression and a newly discovered form of long-term potentiation of synapses between parallel fibers and Purkinje neurons in young adult cerebellar slices. ..
  40. PEDIATRIC ONCOLOGY GROUP
    Yaddanapudi Ravindranath; Fiscal Year: 2002
    ....
  41. Reversal of 5-FU Resistance by Arsenic Trioxide in Colorectal Carcinoma
    Bach Ardalan; Fiscal Year: 2008
    ..Aim 2: Determine if ATO administration down regulates the expression of thymidylate synthase in tumor and in PBMC in patients receiving ATO + 5-FU. [unreadable] [unreadable] [unreadable]..
  42. Resistance and Response Mechanisms to Prostate Cancer Therapy
    TOMASZ BEER; Fiscal Year: 2009
    ..We will test the effectiveness of novel treatments that exploit newly discovered targets in the laboratory and lay the foundation for human trials to develop effective prostate cancer treatment. ..
  43. FAS/APO-1 MEDIATED APOPTOSIS
    Robert Fine; Fiscal Year: 2002
    ..Thus, the selective and rapid induction of apoptosis occurring only in cancer cells carrying p53 abnormalities could be a powerful therapeutic modality for the treatment of cancer. ..
  44. Advancing High Throughput Flow Cytometry
    Bruce S Edwards; Fiscal Year: 2010
    ....
  45. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2002
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  46. Nanostructure Devices for Measuring Cell Mechanics
    Michael Sheetz; Fiscal Year: 2009
    ..These studies have many practical applications in tissue engineering and in designing potential therapies for wound healing, cancer and a variety of disorders. ..
  47. PHYSICOCHEMICAL INVESTIGATION OF TASTE
    Vijay Lyall; Fiscal Year: 2010
    ..The research will reveal how the sour taste defense mechanism functions to prevent the ingestion of acids. ..
  48. Study of anti-angiogenesis enhanced radiotherapy
    Robert Griffin; Fiscal Year: 2008
    ..The information to be obtained in this study will be a vital part of design and implementation of large animal and human clinical trials. ..
  49. Tissue Chips for Toxicology Evaluation
    A Gandolfi; Fiscal Year: 2004
    ..These studies should validate if we have developed an innovative approach to rapidly profile the toxicity of potential chemotherapeutic agents. ..
  50. TNF-Induced Apoptosis of Lymphocytes in Aged Humans
    Sudhir Gupta; Fiscal Year: 2004
    ..These studied should mechanism (s) for increased TNF-a-induced apoptosis during aging. ..
  51. Acquisition of FACSVantage SE Flow Cytometer
    Yair Gazitt; Fiscal Year: 2004
    ..The new equipment will also widen the user's base, save sort time, reduce costs for users and will render sorting affordable to new users, especially in cases where low frequency (<1%) cell populations are sorted. ..
  52. LIPOCORTINS (ANNEXINS) AND METAL-INDUCED MUTAGENESIS
    Fusao Hirata; Fiscal Year: 2003
    ..Our proposed research will provide further insights to understanding of the molecular mechanisms of carcinogenesis, genetic instability and pathological diseases associated with the formation of mutations by heavy metals. ..
  53. Oregon Prostate Cancer Conference 2001
    TOMASZ BEER; Fiscal Year: 2003
    ....
  54. Assay for Formylpeptide Receptor Family Ligands(RMI)
    Bruce Edwards; Fiscal Year: 2005
    ..We expect that such compounds will prove to be important tools with which to advance the understanding and therapy of inflammation-associated diseases. ..
  55. Defibrotide for the treatment of severe hepatic veno-cc*
    Paul Richardson; Fiscal Year: 2007
    ..Abstract Not Provided ..
  56. Mechanism of SOD mimetic activity of vacancy-engineered ceria nanoparticles
    William Self; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  57. A Novel Vitamin D Target in Human Prostate Cancer
    TOMASZ BEER; Fiscal Year: 2007
    ..New treatment targets are needed to develop new drugs to treat prostate cancer, the most commonly diagnosed cancer and the second-leading cancer killer in US men. [unreadable] [unreadable]..
  58. Role of Molecular Chaperones in hERG Processing
    Eckhard Ficker; Fiscal Year: 2008
    ..abstract_text> ..
  59. Cellular Regulation of Salt Taste Transduction
    Vijay Lyall; Fiscal Year: 2008
    ..The identification of natural and synthetic analogues similar to cetylpyridinium chloride that modulate the non-specific cation receptor channel may be potentially useful as salt taste enhancers or suppressers. ..
  60. IMMUNOTOXICITY OF POLYCYCLIC AROMATIC HYDROCARBONS
    Scott Burchiel; Fiscal Year: 2001
    ..Finally, in Aim 4 we will assess the role of monocyte and P450 expression by Western blot and RT-PCR methods in subsets of HPBMC and human cell lines (above). ..
  61. PATHOGENESIS AND THERAPY OF ACUTE PROMYELOCYTIC LEUKEMIA
    Scott Kogan; Fiscal Year: 2003
    ....